- In the past quarter, Ligand Pharmaceuticals reported second-quarter 2026 revenue of US$63.69 million, up from US$47.63 million a year earlier, with net income rising to US$48.51 million and diluted earnings per share from continuing operations reaching US$2.22.
- For the first half of 2026, Ligand moved from a net loss to net income and reaffirmed its full-year outlook for total revenue of US$270 million to US$310 million and GAAP net income of US$107 million to US$118 million, underscoring a continuation of its current financial plan.
- With Ligand reaffirming its 2026 earnings guidance after this sharp year-over-year profit improvement, we'll examine how this shapes its investment narrative.
Find 52 companies with promising cash flow potential yet trading below their fair value.
Ligand Pharmaceuticals Investment Narrative Recap
To own Ligand Pharmaceuticals, you need to believe in its royalty focused model and the durability of its key partnered drugs. The latest quarter’s sharp swing to profitability supports that story, but the most important short term catalyst and biggest risk still lie in how reliably partners convert late stage assets into sustained royalties. This quarter’s results do not materially change those execution and concentration risks, even if they strengthen the company’s financial footing.
The most relevant recent announcement here is Ligand’s reaffirmed 2026 guidance for total revenue of US$270 million to US$310 million and GAAP net income of US$107 million to US$118 million. Holding guidance steady after a strong second quarter ties this earnings beat directly to the existing plan and puts more focus on whether royalty streams from assets like Filspari and Ohtuvayre can support that range without exposing shareholders to outsized single product setbacks.
Yet despite the strong recent quarter, investors should be aware that concentrated exposure to a handful of partnered drugs could still...
Read the full narrative on Ligand Pharmaceuticals (it's free!)
Ligand Pharmaceuticals' narrative projects $449.0 million revenue and $232.0 million earnings by 2029. This requires 17.8% yearly revenue growth and about a $78 million earnings increase from $153.6 million today.
Uncover how Ligand Pharmaceuticals' forecasts yield a $323.30 fair value, a 10% upside to its current price.
Exploring Other Perspectives
While consensus focuses on steadier growth, the most optimistic analysts were assuming revenue near US$538 million and earnings of about US$277 million by 2029, which is a far more ambitious story than today’s guidance and hinges heavily on the large, long dated royalty pipeline actually converting into cash flows.
Explore 2 other fair value estimates on Ligand Pharmaceuticals - why the stock might be worth as much as 47% more than the current price!
Decide For Yourself
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
- A great starting point for your Ligand Pharmaceuticals research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
- Our free Ligand Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Ligand Pharmaceuticals' overall financial health at a glance.
Searching For A Fresh Perspective?
Every day counts. These free picks are already gaining attention. See them before the crowd does:
- Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.
- We've uncovered the 8 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
- Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com